KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Aquestive Therapeutics (AQST) over the last 6 years, with Q3 2025 value amounting to -$1.3 million.

  • Aquestive Therapeutics' Change in Account Payables fell 16961.62% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 41583.51%. This contributed to the annual value of $2.8 million for FY2024, which is 37274.51% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Change in Account Payables stood at -$1.3 million for Q3 2025, which was down 16961.62% from -$323000.0 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Change in Account Payables registered a high of $2.6 million during Q4 2024, and its lowest value of -$3.0 million during Q2 2024.
  • Over the past 5 years, Aquestive Therapeutics' median Change in Account Payables value was $182000.0 (recorded in 2022), while the average stood at $257684.2.
  • Its Change in Account Payables has fluctuated over the past 5 years, first crashed by 104723.62% in 2021, then soared by 127032.97% in 2023.
  • Aquestive Therapeutics' Change in Account Payables (Quarter) stood at $2.1 million in 2021, then tumbled by 153.6% to -$1.1 million in 2022, then grew by 5.07% to -$1.1 million in 2023, then soared by 346.82% to $2.6 million in 2024, then tumbled by 149.54% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$323000.0 for Q2 2025, and $1.9 million during Q1 2025.